Culley Brian M 4

4 · Lineage Cell Therapeutics, Inc. · Filed Feb 13, 2026

AI-generated summary of this filing

Updated Feb 14, 2026

Lineage (LCTX) CEO Brian Culley Receives RSUs; Shares Withheld

What Happened

Brian M. Culley, President, CEO and Director of Lineage Cell Therapeutics (LCTX), had 31,250 restricted stock units (RSUs) vest and convert into 31,250 common shares on Feb 11, 2026. To satisfy statutory tax withholding, the issuer withheld 12,869 of those shares at $1.80 per share for a withholding value of $23,164. The filing shows conversion/exercise (code M) and a tax-withholding disposition (code F).

Key Details

Transaction date: Feb 11, 2026; Form 4 filed Feb 13, 2026 (timely).
Conversion: 31,250 RSUs vested and converted into 31,250 shares (code M).
Tax withholding: 12,869 shares withheld at $1.80/share = $23,164 (code F). Filing notes no open‑market sale of shares in connection with the withholding.
Footnotes: These RSUs were part of a 124,997‑RSU grant dated Feb 11, 2022 that vests ~25% each year (F4). RSUs convert one‑for‑one into common shares (F1). The filing also reports a conversion/disposition line of 31,250 shares at $0 consistent with RSU settlement mechanics (see footnotes).
Shares owned after the transaction: not specified in the provided filing details.

Context

This was an award/vesting event (not an open‑market buy or sell). The issuer withheld shares to cover withholding taxes (a common cashless withholding method) rather than the insider selling shares on the open market.
Transaction codes: M = exercise/conversion of derivative (RSU vesting here); F = payment of exercise price or tax liability (tax withholding).
Such vesting and withholding are routine compensation events and do not, by themselves, indicate a buy/sell signal from the insider.

Form 4

Period: 2026-02-11

DirectorPresident and CEO

Transactions

Exercise/Conversion
Common Shares
[F1][F2]
2026-02-11+31,250→ 253,385 total
Tax Payment
Common Shares
[F3][F2]
2026-02-11$1.80/sh−12,869$23,164→ 240,516 total
Exercise/Conversion
Restricted Stock Units
[F4]
2026-02-11−31,250→ 0 total
Exercise: $0.00→ Common Shares (31,250 underlying)

Footnotes (4)

[F1]Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis.
[F2]Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options.
[F3]Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 31,250 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction
[F4]The Reporting Person was granted 124,997 RSUs on February 11, 2022, that vested with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026.

Signature

/s/ Brian M. Culley|2026-02-13

1 file